Spontaneous Cervical Artery Dissection: A Case Series

Authors:

Amedra Basgaran MB BChir (a.basgaran@nhs.net, Northwick Park Hospital), Catherine Hsiao-wei Hsu MB BChir (catherine.hsu@nhs.net, Chelsea and Westminster Hospital), Aravinth Sivagnanaratnam MRCP (UK) (a.sivagnanaratnam@nhs.net, Northwick Park Hospital)

Corresponding Author:

Dr Amedra Basgaran

Department of Stroke Medicine, Northwick Park Hospital, Watford Road, London, HA1 3UJ

02088693232

a.basgaran@nhs.net

Keywords:

Anticoagulants

Antiplatelets

Cervical Artery Dissection

Stroke

Word Count: 1891. Tables 3; Figures 3.

Disclosures:

None.

Sources of Funding:

None.

Abstract

Cervical artery dissection refers to dissection of the vertebral or carotid arteries, and accounts for up to 20% of strokes in those under 45. Antithrombotic therapy is therefore essential to limit thrombosis at the site of injury and distal neuronal damage. However, the exact choice of drugs, timing and duration of therapy remain a challenging decision.

A review of data was conducted on three cases of unprovoked cervical dissection at our stroke center between 2017 and 2020. They include bilateral internal carotid artery dissection, right vertebral artery dissection, and left internal carotid artery dissection.

Three key outcomes were identified: narrowing, occlusion and pseudoaneurysm; such outcomes dictated our management approach. Two patients were given antiplatelet therapy for at least one year. The patient with bilateral dissection was perceived to have higher thromboembolic risk, due to the presence of a free-floating thrombus. Thus, he was anticoagulated for a year, and thereafter given antiplatelet therapy.

The evidence behind long-term management of carotid artery dissection remains equivocal. There is no strong evidence favouring anticoagulation over antiplatelets or vice versa. Anticoagulation tends to be preferred in cases of severe stenosis, occlusion or pseudoaneurysm, to reduce the risk of thromboembolic phenomena. Anti-platelets are preferred where there is a high risk of haemorrhagic transformation or contraindication to anticoagulation. The duration of secondary prevention is similarly unclear. Advances in radiology and increased follow-up have resulted in uncertainty on the management of incomplete healing at the six-month point. Varying clinical practice has been identified and there is a lack of a clear guideline. We propose continuing antithrombotic therapy in cases of incomplete healing, as in our case series. Nevertheless, we require more data on the subject and thus suggest an initial nation-wide survey to compare the different management strategies followed by large-scale retrospective analyses comparing long-term outcomes.

Introduction

Cervical artery dissection (CAD) refers to dissection of the vertebral or carotid arteries.

It accounts for up to 20% of strokes in those under 45[1] due to association with a high risk of intracranial microembolisms[2]. It thus has potentially devastating consequences, including neuropathy, ischaemic stroke, subarachnoid haemorrhage and death.

Antithrombotic therapy is therefore essential to limit thrombosis at the site of injury and distal CAD-related neuronal damage. However, the exact choice of drugs, timing and duration of therapy remain a challenging decision. Furthermore, identification of underlying risk factors can assist with reducing further risk of dissection; yet there lacks a clear guideline for such investigations.

Methods

A review of data was conducted on three cases of cervical dissection at our stroke centre between 2017 and 2020. We compare and contrast their presenting and imaging features, management approaches and outcome. All three patients have been followed up at 6 monthly intervals, with computed tomography angiography performed to assess progress. Written informed consent was obtained from all patients for their anonymized information to be published in this case series.

Results

All cases were unprovoked and involved either the carotid or vertebral artery. Presenting features varied based on vascular territory affected, and are described in Table 1. The cases include bilateral internal carotid artery dissection, right vertebral artery dissection, and left internal carotid artery dissection.

The investigation of underlying risk factors was taken further with patient 1, given his bilateral nature. This patient had two risk factors identified: borderline hypertension and a habit of “cracking his neck”. Although there are no reports of this mechanism, there are reported cases of carotid artery dissection following cervical manipulation coupled with an underlying arteriopathy such as idiopathic cystic medial degeneration[3], and minor trauma such as coughing [4]. This habit coupled with his borderline hypertension is a potential but weak hypothesis explaining his dissection.

There are 3 key outcomes identified in cervical artery dissection: narrowing, occlusion and pseudoaneurysm; all of which are demonstrated in this case series. Such outcomes have dictated our management approach. Two patients were given antiplatelet therapy for at least one year. The patient with bilateral dissection was perceived to have higher thromboembolic risk, due to his bilateral nature and also the presence of a free-floating thrombus. Thus, he was anticoagulated with warfarin for a year, and thereafter given antiplatelet therapy.

Discussion

Given the rarity of bilateral spontaneous carotid artery dissection, we proceeded to investigate for other underlying conditions that could have predisposed this patient to such a pathology (Table 1). We have comprised a list of risk factors investigated for and grouped them according to category: autoimmune causes such as vasculitis of any origin, collagenous causes such as Marfan's syndrome, structural causes such as autosomal polycystic kidney disease, and toxin-mediated causes such as cocaine induced vasospasm. All investigations have come back as negative.

Genetic testing was negative for collagen vascular disease. A variant of unknown significance was identified in the FBN2 gene on the FTAAD (familial thoracic aorta and dissection) gene panel. This was thought unlikely to be related to the carotid artery dissection as such mutations are usually associated with Beals syndrome (congenital contractural arachnodactyly).

A literature search identified further conditions to consider, namely osteogenesis imperfecta and hyperhomocysteinemia[5]. Furthermore, there are reported cases where predisposing risk factors are yet to be defined as conditions, such as carotid artery tortuosity identified on CT angiogram imaging[6].

Cervical artery dissection is treated with anti-platelets or anti-coagulation, with no evidence favouring one[7,8,9]. A number of meta-analyses [10,11] as well as a powerful multicenter prospective RCT (CADISS) [12] found no significant difference between the two therapies. The literature suggests anticoagulation in cases of severe stenosis, occlusion or pseudoaneurysm, on the basis that they reduce the risk of thromboembolic phenomena[7,8].

In contrast, antiplatelets are preferred in patients with a poor prognosis or large infarcts, to reduce the risk of haemorrhagic transformation[7,9,13].

The suggested time-length for treatment is more unclear. Radiographic improvement in cervical artery dissection largely takes place in the first 6 months[14], suggesting a similar time length for treatment[7]. Yet, this timeline is also confounded by the varying complications that can occur, such as narrowing of the artery or the formation of a pseudo-aneurysm. In such cases where there is incomplete healing at the six-month point, there are no trials or clear guideline on how long to treat with anti-thrombotic therapy.

A small survey of clinicians at the national UK Stroke Forum in 2019 on their management of cervical artery dissection similarly reflected varying practice (Table 3). The majority preferred antiplatelet therapy, with some clinicians reportedly using dual antiplatelet therapy. Anticoagulation was preferred in cases where there was a free-floating thrombus. The duration of therapy also varied with some clinicians opting for 6 months, and some opting for lifelong therapy especially when using antiplatelets. Such variation in practice highlights gaps in knowledge requiring rectification.

Conclusion

This case series has provided us with valuable learning points on how to investigate and treat patients with spontaneous carotid artery dissection. The evidence behind long-term management of carotid artery dissection however remains equivocal. There is no strong evidence favouring anticoagulation over antiplatelets or vice versa. Anticoagulation tends to be preferred in cases of severe stenosis, occlusion or pseudoaneurysm, on the basis that anticoagulation reduces the risk of thromboembolic phenomena. Anti-platelets are preferred where there is a high risk of haemorrhagic transformation or contraindication to anticoagulation, and are a more convenient choice. Furthermore, the duration of secondary prevention is unclear. Advances in radiology and increased follow-up have resulted in uncertainty on the management of incomplete healing at the six-month point. Varying clinical practice has been identified and there is a lack of a clear guideline. We propose continuing antithrombotic therapy in cases of incomplete healing, as in our case series. Nevertheless, we require more data on the subject and thus suggest an initial nation-wide survey to compare the different management strategies, particularly looking at duration of therapy, followed by large-scale retrospective analyses comparing the long-term outcomes associated with these different practices.

Acknowledgements

Nil.

References

1. Bogousslavsky J, Pierre P. Ischaemic stroke in patients under age 45. *Neurol Clin.* 1992;10(1):113-24.
2. Srinivasan J, Newell DW, Sturzenegger M, Mayberg MR, Winn HR. Transcranial Doppler in the evaluation of internal carotid artery dissection. *Stroke.* 1996;27:1226–1230.
3. Carpieaux M, Michotte A, Van Varenbergh D, Marichal MP. Spontaneous bilateral carotid artery dissection following cervical manipulation. *Leg Med (Tokyo)* 2012;14(5):249-51.
4. Levy M, Arfi-Levy E, Maimon S. Therapeutic and diagnostic implication of inadequate circle of willis in a patient with acute spontaneous bilateral internal carotid artery dissection: case report and review of the literature. *Case Rep Neurol.* 2012;4(1):1-9.
5. Luo H, Liu B, Hu J, Wang X, Zhan S, Kong W. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in cervical artery dissection: a meta-analysis. *Cerebrovasc Dis.* 2014;37(5):313-22.
6. Kim ST, Brinjikji W, Lehman VT, Carr CM, Luetmer PH, Rydberg CH. Association between carotid artery tortuosity and carotid dissection: a case-control study. *J Neurosurg Sci.* 2018;62(4):413-7.
7. Debette S, Leys D. Cervical-artery dissections: predisposing factors, diagnosis, and outcome. *Lancet Neurol.* 2009;8(7):668–78.

8. Patel RR, Adam R, Maldjian C, Lincoln CM, Yuen A, Arneja A. Cervical carotid artery dissection: current review of diagnosis and treatment. *Cardiol Rev* 2012;20(3):145–52.
9. Engelter ST, Brandt T, Debette S, Caso V, Lichy C, Pezzini A et al. Antiplatelets versus anticoagulation in cervical artery dissection. *Stroke* 2007;38(9):2605–11.
10. Kennedy F, Lanfranconi S, Hicks C. Antiplatelets vs anticoagulation for dissection: CADISS nonrandomized arm and meta-analysis. *Neurology* 2012;79(7):686–689.
11. Sarikaya H, da Costa BR, Baumgartner RW. Antiplatelets versus anticoagulants for the treatment of cervical artery dissection: bayesian meta-analysis. *PLoS One* 2013;8(9):1-13.
12. Markus H, Hayter E, Levi C, Feldman A, Venables G, Norris J et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. *Lancet Neurol.* 2015;14(4):361-367.
13. Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. *Cochrane Database Syst Rev.* 2010;(10):CD000255.
14. Kasner SE, Hankins LL, Bratina P, Morgenstern LB. Magnetic resonance angiography demonstrates vascular healing of carotid and vertebral artery dissections. *Stroke* 1997;28:1993-1997.

Figure Legends

Figure 1. Example CT Imaging of Patient 2

A, Initial CT Head identifying Right Vertebral Artery Dissection

B, Follow Up CT Head at 6 Months identifying Right Vertebral Artery Occlusion

Figure 2. CT Head of Patient 1 in Axial Plane identifying Left Carotid Artery Dissection

Flap and Right Carotid Artery Narrowed Lumen with a Mural Haematoma

Figure 3. 2 Year Follow up CT Head of Patient 1 in Coronal Plane identifying Left Carotid

Artery Pseudoaneurysm and Right Carotid Artery Recanalisation

Table Legends

Table 1. Presenting features, CT findings, outcome and management plans of three patients presenting with cervical artery dissection at our centre.

Table 2. Risk Factors identified for Carotid Artery Dissection and Investigations performed to rule out such causes.

Table 3. Survey of Management of Cervical Artery Dissection by Clinicians at UK Stroke Forum 2019

Online Supplement

Nil

Patient:	1	2	3
Presentation	<u>1st dissection:</u> Sudden onset headache and neck pain. Temporary right sided arm weakness <u>2nd dissection:</u> Sudden onset headache and neck pain. Temporary left sided arm weakness.	Sudden onset vertigo and vomiting, resolved after 3 days.	Sudden onset left blurred vision, right hand numbness, expressive dysphasia, unsteadiness.
CT Angiogram Findings	Left internal carotid artery dissection Right internal carotid artery dissection	Right vertebral artery dissection Right cerebellar infarct	Left internal carotid artery dissection Left middle cerebral artery territory infarct
Co-Morbidities	Borderline hypertension	Meningitis 5 years prior to event. Smoker	Smoker
Outcome at 6 Months	Left pseudoaneurysm Right narrowing	Occlusion	Narrowing
Outcome on Latest Review	2 years: Left pseudoaneurysm, Right recanalisation	1 year: Occlusion	6 months: Narrowing
Management	Warfarin for 1 year Clopidogrel 75mg ongoing	Aspirin 300mg for 2 weeks	Aspirin 300mg for 2 weeks

		Clonidogrel 75mg ongoing	Clonidogrel 75mg ongoing

Category	Risk Factors	Salient Negative Investigations
Autoimmune	Antiphospholipid Syndrome Vasculitides	Antiphospholipid antibodies ANCA, ANA, ENA, RhF, ESR
Collagenous	Ehlers-Danlos Syndrome Marfan's disease Collagen vascular disease	Genetic testing
Structural	Autosomal polycystic kidney disease Fibromuscular dysplasia	Renal Ultrasound CT angiogram
Toxin	Cocaine-induced vasospasm	Urine toxicology screen

	<u>Preference on Therapy</u>	<u>Factors affecting Choice of Therapy</u>	<u>Duration of therapy</u>
1	Anticoagulant	Anticoagulation if ischaemic changes on imaging and young patients.	6 months
2	Antiplatelet	Anticoagulation if free-floating thrombus present.	Lifelong if antiplatelet, 6 months if anticoagulant
3	Antiplatelet	Antiplatelet if young and no comorbidities. Anticoagulation if older with ischaemic heart disease.	6 months
4	Antiplatelet	Unsure	Unsure
5	Antiplatelet	Unsure	Unsure
6	Antiplatelet	Unsure	Lifelong
7	Antiplatelet	Initial antiplatelet therapy. If no healing at 6 months, anticoagulation.	6 months
8	Antiplatelet	Anticoagulation if free-floating thrombus present.	6 months
9	Antiplatelet	Anticoagulation if comorbidities resulting in pro-coagulable state.	Lifelong
10	Both	Unsure	Unsure